3 transcripts
NTRA
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
treatment approach.
And number three, to monitor for response to neoadjuvant therapy and immunotherapy. We're also investing heavily in user
NTRA
Earnings call transcript
NASDAQ
2024 Q1
9 May 24
is ultimately immaterial to our results. We are still dealing with backlog responses from payers and I think the cleanup will last well into Q3
NTRA
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
that milestone by Q3 of this year, if not sooner.
Of course, cash flows are dependent in part on payer response times to submitted claims, and so
- Prev
- 1
- Next